SecBot SecBot
SECBOTREPLAY Home › Report › NRXP

NRXP · NRx Pharmaceuticals announced the presentation of a peer-reviewed…

NRx Pharmaceuticals, Inc. · PRESS-RELEASE filed Jun 5, 2026 at 08:50 ET

At the news

BULLISHIMPACT 7/10

PRESS-RELEASE filed Jun 5, 2026 at 08:50 ET

NRx Pharmaceuticals announced the presentation of a peer-reviewed poster at the 2026 ASCP conference showing that IV ketamine (NRX-100) demonstrated significantly higher remission and response rates vs. intranasal esketamine in a real-world study of over 10,000 patients. The data supports NRx's NDA filing for NRX-100 in suicidal depression, with the FDA emphasizing real-world evidence via a recent Executive Order and Congressional language.

  • IV ketamine patients showed 50% higher odds of remission (OR 1.51; P<.001) and 22% higher odds of response (OR 1.22; P<.003) vs. intranasal esketamine.
  • Study analyzed 8,224 IV ketamine and 1,830 intranasal esketamine patients from 800 community clinics.
  • 34% of IV ketamine patients achieved remission vs. 26% for esketamine; 63% vs. 58% response rate.
  • NRx has filed an NDA for NRX-100 (IV ketamine) with a National Priority Voucher Program application for suicidal depression.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access